Former MLB base-stealer Dave Roberts battling Hodgkin's

Dave Roberts, a former MLB outfielder known for his prolific base-stealing prowess, and who now works as a special assistant in the San Diego Padres' baseball operations department, was diagnosed with Hodgkin's lymphoma this past spring and has begun treatment including chemotherapy.

Despite suffering some tough days following chemo, Roberts told MLB.com that his "spirits continue to be high and, if you know me, they will continue to be. I expect to be fully recovered."

During ten MLB seasons, Roberts was a career .266 hitter, accumulating 243 stolen bases over that time span, including stealing second base for the Red Sox against the Yankees in the 2004 ALCS. The steal put Roberts in scoring position, allowing the Sox to win and kickstarting their unprecedented comeback from being down three games to zero to win the ALCS and ultimately, the World Series.

By Ross Bonander

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap